Article citationsMore>>

Fortuna, A., Alves, G. and Falcão, A. (2011) In Vitro and in Vivo Relevance of the P-Glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol. Journal of Bioequivalence & Bioavailability, 1, 1-23.
https://doi.org/10.4172/jbb.s2-001

has been cited by the following article:

• TITLE: Role of P-Gp in Treatment of Cancer

  AUTHORS: Venkata Sai Nithin Reddy Yendapalli, Kelley Williams, Terry Oroszi

  KEYWORDS: P-Glycoprotein (P-Gp), Multi-Drug Resistance (MDR), Cancer Treatment, ABC Transporters, Chemotherapy Resistance, P-Gp Inhibitors, Drug Efflux Mechanisms Fourth-Generation Inhibitors

  JOURNAL NAME: Journal of Cancer Therapy, Vol.16 No.1, January 3, 2025

  ABSTRACT: P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) family of transporters, plays a crucial role in the development of multi-drug resistance (MDR) in cancer treatment. P-gp actively pumps chemotherapeutic drugs out of cancer cells, reducing their intracellular concentrations and thereby diminishing their efficacy. This review explores the mechanisms by which P-gp contributes to MDR, including intrinsic and acquired resistance. It also discusses various strategies to inhibit P-gp, such as blocking drug binding sites, interfering with ATP hydrolysis, and altering cell membrane integrity. The potential of fourth-generation P-gp inhibitors and other novel approaches to enhance the effectiveness of cancer therapies is also examined. Understanding and overcoming P-gp-mediated MDR is essential for improving therapeutic outcomes in cancer patients.